PureTech challenges Roche’s Esbriet in head-to-head IPF trialRoche’s idiopathic pulmonary fibrosis (IPF) therapy Esbriet is already being squeezed by its main rival in the market, Share XPureTech challenges Roche’s Esbriet in head-to-head IPF trialhttps://pharmaphorum.com/news/puretech-challenges-roches-esbriet-in-head-to-head-ipf-trial/
Biogen looks beyond Spinraza in SMA with Ionis dealSpinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with Share XBiogen looks beyond Spinraza in SMA with Ionis dealhttps://pharmaphorum.com/news/biogen-looks-beyond-spinraza-in-sma-with-ionis-deal/
Blow for Novartis as ligelizumab can’t top Xolair in phase 3Novartis’ big-selling IgE inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many Share XBlow for Novartis as ligelizumab can’t top Xolair in phase 3https://pharmaphorum.com/news/blow-for-novartis-as-ligelizumab-cant-top-xolair-in-phase-3/
Roche builds case for TIGIT combo in untreated lung cancerRoche’s closely-watched combination of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq has shown long-term efficacy in an ongoing Share XRoche builds case for TIGIT combo in untreated lung cancerhttps://pharmaphorum.com/news/roche-builds-case-for-tigit-combo-in-untreated-lung-cancer/
AI specialist Recursion nabs multibillion-dollar Roche partnershipRoche has formed a decade-long alliance with Recursion Pharma that will focus on using machine learning and “industrialised” Share XAI specialist Recursion nabs multibillion-dollar Roche partnershiphttps://pharmaphorum.com/news/ai-specialist-recursion-nabs-multibillion-dollar-roche-partnership/
EU approves Roche’s Actemra for severe COVID-19The European Commission has moved swiftly to grant full approval to Roche’s Actemra/RoActemra as a treatment for severe Share XEU approves Roche’s Actemra for severe COVID-19https://pharmaphorum.com/news/eu-approves-roches-actemra-for-covid-19/
After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancerEli Lilly’s RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced Share XAfter Scotland says no, NICE backs Lilly’s Retsevmo for lung cancerhttps://pharmaphorum.com/news/after-scotland-says-no-nice-backs-lillys-retsevmo-for-lung-cancer/
ASH abstract drop backs Roche’s Polivy in first-line lymphomaRoche trumpeted a top-line results of the POLARIX trial of its Polivy therapy in previously-untreated B-cell lymphoma, and Share XASH abstract drop backs Roche’s Polivy in first-line lymphomahttps://pharmaphorum.com/news/ash-abstract-drop-backs-roches-polivy-in-first-line-lymphoma/
Roche, Blueprint’s RET cancer drug Gavreto cleared in EURoche and Blueprint Medicines have opened a second front in their rivalry with Eli Lilly in RET-mutated cancers, Share XRoche, Blueprint’s RET cancer drug Gavreto cleared in EUhttps://pharmaphorum.com/news/roche-blueprints-ret-cancer-drug-gavreto-cleared-in-eu/
